Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2024

Open Access 01-12-2024 | Laryngectomy | Study Protocol

Prophylactic pectoralis major flap to compensate for increased risk of pharyngocutaneous fistula in laryngectomy patients with low skeletal muscle mass (PECTORALIS): study protocol for a randomized controlled trial

Authors: Maartje A. van Beers, Caroline M. Speksnijder, Carla H. van Gils, Geert W.J. Frederix, Jan Willem Dankbaar, Remco de Bree

Published in: BMC Cancer | Issue 1/2024

Login to get access

Abstract

Background

Total laryngectomy (TL) is a surgical procedure commonly performed on patients with advanced laryngeal or hypopharyngeal carcinoma. One of the most common postoperative complications following TL is the development of a pharyngocutaneous fistula (PCF), characterized by a communication between the neopharynx and the skin. PCF can lead to extended hospital stays, delayed oral feeding, and compromised quality of life. The use of a myofascial pectoralis major flap (PMMF) as an onlay technique during pharyngeal closure has shown potential in reducing PCF rates in high risk patients for development of PCF such as patients undergoing TL after chemoradiation and low skeletal muscle mass (SMM). Its impact on various functional outcomes, such as shoulder and neck function, swallowing function, and voice quality, remains less explored. This study aims to investigate the effectiveness of PMMF in reducing PCF rates in patients with low SMM and its potential consequences on patient well-being.

Methods

This multicenter study adopts a randomized clinical trial (RCT) design and is funded by the Dutch Cancer Society. Eligible patients for TL, aged ≥ 18 years, mentally competent, and proficient in Dutch, will be enrolled. One hundred and twenty eight patients with low SMM will be centrally randomized to receive TL with or without PMMF, while those without low SMM will undergo standard TL. Primary outcome measurement involves assessing PCF rates within 30 days post-TL. Secondary objectives include evaluating quality of life, shoulder and neck function, swallowing function, and voice quality using standardized questionnaires and functional tests. Data will be collected through electronic patient records.

Discussion

This study’s significance lies in its exploration of the potential benefits of using PMMF as an onlay technique during pharyngeal closure to reduce PCF rates in TL patients with low SMM. By assessing various functional outcomes, the study aims to provide a comprehensive understanding of the impact of PMMF deployment. The anticipated results will contribute valuable insights into optimizing surgical techniques to enhance patient outcomes and inform future treatment strategies for TL patients.

Trial registration

NL8605, registered on 11-05-2020; International Clinical Trials Registry Platform (ICTRP).
Literature
1.
Markou KD, Vlachtsis KC, Nikolaou AC, Petridis DG, Kouloulas AI, Daniilidis IC. Incidence and predisposing factors of pharyngocutaneous fistula formation after total laryngectomy. Is there a relationship with Tumor recurrence? European Archives of Oto-Rhino-Laryngology. 2004;261(2):61–7.
2.
Magdy EA. Surgical closure of postlaryngectomy pharyngocutaneous fistula: a defect based approach. Eur Arch Otorhinolaryngol. 2008;265(1):97–104.PubMedCrossRef
3.
Wang M, Xun Y, Wang K, Lu L, Yu A, Guan B, et al. Risk factors of pharyngocutaneous fistula after total laryngectomy: a systematic review and meta-analysis. Eur Arch Otorhinolaryngol. 2020;277(2):585–99.PubMedCrossRef
4.
Lansaat L, van der Noort V, Bernard SE, Eerenstein SEJ, Plaat BEC, Langeveld TAPM, et al. Predictive factors for pharyngocutaneous fistulization after total laryngectomy: a Dutch Head and Neck Society audit. Eur Arch Otorhinolaryngol. 2018;275(3):783–94.PubMedCrossRef
5.
Paydarfar JA, Birkmeyer NJ. Complications in head and neck Surgery: a meta-analysis of postlaryngectomy pharyngocutaneous fistula. Arch Otolaryngol Head Neck Surg. 2006;132(1):67–72.PubMedCrossRef
6.
Hasan Z, Dwivedi RC, Gunaratne DA, Virk SA, Palme CE, Riffat F. Systematic review and meta-analysis of the Complications of salvage total laryngectomy. Eur J Surg Oncol. 2017;43(1):42–51.PubMedCrossRef
7.
Busoni M, Deganello A, Gallo O. Pharyngocutaneous fistula following total laryngectomy: analysis of risk factors, prognosis and treatment modalities. Acta Otorhinolaryngol Ital. 2015;35(6):400–5.PubMedPubMedCentralCrossRef
8.
Ganly I, Patel S, Matsuo J, Singh B, Kraus D, Boyle J, et al. Postoperative Complications of salvage total laryngectomy. Cancer. 2005;103(10):2073–81.PubMedCrossRef
9.
Davies JC, Hugh S, Rich JT, De Almeida JR, Gullane PJ, Orsini M, et al. Association of Pharyngocutaneous Fistula with Cancer outcomes in patients after laryngectomy: a Multicenter Collaborative Cohort Study. JAMA Otolaryngol Head Neck Surg. 2021;147(12):1027–34.PubMedCrossRef
10.
McLean JN, Nicholas C, Duggal P, Chen A, Grist WG, Losken A, et al. Surgical management of pharyngocutaneous fistula after total laryngectomy. Ann Plast Surg. 2012;68(5):442–5.PubMedCrossRef
11.
Anschütz L, Nisa L, Elicin O, Bojaxhiu B, Caversaccio M, Giger R. Pectoralis major myofascial interposition flap prevents postoperative pharyngocutaneous fistula in salvage total laryngectomy. Eur Arch Otorhinolaryngol. 2016;273(11):3943–9.PubMedCrossRef
12.
Sayles M, Grant DG. Preventing pharyngo-cutaneous fistula in total laryngectomy: a systematic review and meta-analysis. Laryngoscope. 2014;124(5):1150–63.PubMedCrossRef
13.
Paleri V, Drinnan M, van den Brekel MWM, Hinni ML, Bradley PJ, Wolf GT, et al. Vascularized tissue to reduce fistula following salvage total laryngectomy: a systematic review. Laryngoscope. 2014;124(8):1848–53.PubMedCrossRef
14.
Sharma S, Chaukar DA, Laskar SG, Kapre N, Deshmukh A, Pai P, Chaturvedi P, et al. Role of the pectoralis major myofascial flap in preventing pharyngocutaneous fistula following salvage laryngectomy. J Laryngol Otol. 2016;130(9):860–4.PubMedCrossRef
15.
Guimarães AV, Aires FT, Dedivitis RA, Kulcsar MAV, Ramos DM, Cernea CR, et al. Efficacy of pectoralis major muscle flap for pharyngocutaneous fistula prevention in salvage total laryngectomy: a systematic review. Head Neck. 2016;38(Suppl 1):E2317–21.PubMed
16.
Smith TJ, Burrage KJ, Ganguly P, Kirby S, Drover C. Prevention of postlaryngectomy pharyngocutaneous fistula: the Memorial University experience. J Otolaryngol. 2003;32(4):222–5.PubMedCrossRef
17.
Fitzgerald CWR, Davies JC, de Almeida JR, Rich JT, Orsini M, Eskander A et al. Factors predicting pharyngocutaneous fistula in patients after salvage laryngectomy for laryngeal malignancy – a multicenter collaborative cohort study. Oral Oncol. 2022;134.
18.
Bril SI, Pezier TF, Tijink BM, Janssen LM, Braunius WW, de Bree R. Preoperative low skeletal muscle mass as a risk factor for pharyngocutaneous fistula and decreased overall survival in patients undergoing total laryngectomy. Head Neck. 2019;41(6):1745–55.PubMedPubMedCentralCrossRef
19.
Casasayas M, García-Lorenzo J, Gómez-Ansón B, Medina V, Fernández A, Quer M, et al. Low skeletal muscle mass assessed directly from the 3rd cervical vertebra can predict pharyngocutaneous fistula risk after total laryngectomy in the male population. Eur Arch Otorhinolaryngol. 2022;279(2):853–63.PubMedCrossRef
20.
Yamaguchi T, Makiguchi T, Nakamura H, Yamatsu Y, Hirai Y, Shoda K, et al. Impact of muscle volume loss on acute oral mucositis in patients undergoing concurrent chemoradiotherapy after Oral cancer resection. Int J Oral Maxillofac Surg. 2021;50(9):1195–202.PubMedCrossRef
21.
Bril SI, Al-Mamgani A, Chargi N, Remeijer P, Devriese LA, de Boer JP, et al. The association of pretreatment low skeletal muscle mass with chemotherapy dose-limiting toxicity in patients with Head and Neck cancer undergoing primary chemoradiotherapy with high-dose cisplatin. Head Neck. 2022;44(1):189–200.PubMedCrossRef
22.
Chargi N, Bashiri F, Wendrich AW, Smid EJ, de Jong PA, Huitema ADR, et al. Image-based analysis of skeletal muscle mass predicts cisplatin dose-limiting toxicity in patients with locally advanced Head and Neck cancer. Eur Arch Otorhinolaryngol. 2022;279(7):3685–94.PubMedCrossRef
23.
Wendrich AW, Swartz JE, Bril SI, Wegner I, de Graeff A, Smid EJ, et al. Low skeletal muscle mass is a predictive factor for chemotherapy dose-limiting toxicity in patients with locally advanced Head and Neck cancer. Oral Oncol. 2017;71:26–33.PubMedCrossRef
24.
Ansari E, Chargi N, van Gemert JTM, van Es RJJ, Dieleman FJ, Rosenberg AJWP, et al. Low skeletal muscle mass is a strong predictive factor for Surgical Complications and a prognostic factor in Oral cancer patients undergoing mandibular reconstruction with a free fibula flap. Oral Oncol. 2020;101:104530.PubMedCrossRef
25.
Chargi N, Breik O, Forouzanfar T, Martin T, Praveen P, Idle M, et al. Association of low skeletal muscle mass and systemic inflammation with Surgical Complications and survival after microvascular flap reconstruction in patients with Head and Neck cancer. Head Neck. 2022;44(10):2077–94.PubMedPubMedCentralCrossRef
26.
Surov A, Wienke A. Low skeletal muscle mass predicts relevant clinical outcomes in head and neck squamous cell carcinoma. A meta analysis. Ther Adv Med Oncol. 2021;13.
27.
Chang SW, Hsu CM, Tsai YH, Chang GH, Tsai MS, Huang EI, et al. Prognostic value of third cervical vertebra skeletal muscle index in oral Cavity Cancer: a retrospective study. Laryngoscope. 2021;131(7):E2257–65.PubMedCrossRef
28.
Takenaka Y, Takemoto N, Oya R, Inohara H. Prognostic impact of Sarcopenia in patients with Head and Neck cancer treated with Surgery or radiation: a meta-analysis. PLoS ONE. 2021;16(10 October).
29.
Thureau S, Lebret L, Lequesne J, Cabourg M, Dandoy S, Gouley C, et al. Prospective evaluation of Sarcopenia in Head and Neck cancer patients treated with radiotherapy or radiochemotherapy. Cancers (Basel). 2021;13(4):1–15.CrossRef
30.
Swartz JE, Pothen AJ, Wegner I, Smid EJ, Swart KMA, de Bree R, et al. Feasibility of using head and neck CT imaging to assess skeletal muscle mass in Head and Neck cancer patients. Oral Oncol. 2016;62:28–33.PubMedCrossRef
31.
Heymsfield SB, Wang Z, Baumgartner RN, Ross R. Human body composition: advances in models and methods. Annu Rev Nutr. 1997;17:527–58.PubMedCrossRef
32.
Righini C, Lequeux T, Cuisnier O, Morel N, Reyt E. The pectoralis myofascial flap in pharyngolaryngeal Surgery after radiotherapy. Eur Arch Otorhinolaryngol. 2005;262(5):357–61.PubMedCrossRef
33.
Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365–76.PubMedCrossRef
34.
Sherman AC, Simonton S, Adams DC, Vural E, Owens B, Hanna E. Assessing quality of life in patients with Head and Neck cancer: cross-validation of the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Head and Neck module (QLQ-H&N35). Arch Otolaryngol Head Neck Surg. 2000;126(4):459–67.PubMedCrossRef
35.
Group E. EuroQol*-a new facility for the measurement of health-related quality of life. Health Policy. 1990.
36.
van der Windt DA, van der Heijden GJ, de Winter AF, Koes BW, Devillé W, Bouter LM. The responsiveness of the shoulder disability questionnaire. Ann Rheum Dis. 1998;57(2):82–7.PubMedPubMedCentralCrossRef
37.
Thoomes-de Graaf M, Scholten-Peeters GGM, Duijn E, Karel Y, Koes BW, Verhagen AP. The Dutch Shoulder Pain and Disability Index (SPADI): a reliability and validation study. Qual Life Res. 2015;24(6):1515–9.PubMedCrossRef
38.
Jorritsma W, de Vries GE, Dijkstra PU, Geertzen JHB, Reneman MF. Neck Pain and Disability Scale and Neck Disability Index: validity of Dutch language versions. Eur Spine J. 2012;21(1):93–100.PubMedCrossRef
39.
Govender R, Lee MT, Davies TC, Twinn CE, Katsoulis KL, Payten CL, et al. Development and preliminary validation of a patient-reported outcome measure for swallowing after total laryngectomy (SOAL questionnaire). Clin Otolaryngol. 2012;37(6):452–9.PubMedCrossRef
40.
Speyer R, Heijnen BJ, Baijens LW, Vrijenhoef FH, Otters EF, Roodenburg N, et al. Quality of life in oncological patients with oropharyngeal dysphagia: validity and reliability of the Dutch version of the MD Anderson Dysphagia Inventory and the Deglutition Handicap Index. Dysphagia. 2011;26(4):407–14.PubMedPubMedCentralCrossRef
41.
Crary MA, Mann GDC, Groher ME. Initial psychometric assessment of a functional oral intake scale for dysphagia in Stroke patients. Arch Phys Med Rehabil. 2005;86(8):1516–20.PubMedCrossRef
42.
Jacobson B, Johnson A, Grywalski C, Silbergleit A, Jacobson G, Benninger MS. The Voice Handicap Index (VHI): development and validation. Am J Speech Lang Pathol. 1997;6:66–70.CrossRef
43.
Vafadar AK, Côté JN, Archambault PS. Interrater and Intrarater Reliability and Validity of 3 measurement methods for shoulder-position sense. J Sport Rehabil. 2016;25(1).
44.
Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol. 2006;3(2):77–101.CrossRef
45.
O’Brien BC, Harris IB, Beckman TJ, Reed DA, Cook DA. Standards for reporting qualitative research: a synthesis of recommendations. Acad Med. 2014;89(9):1245–51.PubMedCrossRef
46.
JW Cresswell. Qualitative inquiry and research design. 2nd ed. Thousand Oaks (CA): SAGE Publications; 2007.
47.
Guest G, Bunce A, Johnson L. How many interviews are Enough? An experiment with data saturation and variability. Field Methods. 2006;18(1):59–82.CrossRef
48.
Barsties B, Maryn Y. External validation of the Acoustic Voice Quality Index Version 03.01 with extended representativity. Ann Otol Rhinol Laryngol. 2016;125(7):571–83.PubMedCrossRef
49.
Maryn Y, De Bodt M, Barsties B, Roy N. The value of the acoustic voice quality index as a measure of dysphonia severity in subjects speaking different languages. Eur Arch Otorhinolaryngol. 2014;271(6):1609–19.PubMed
50.
Dindo D, Demartines N, Clavien PA. Classification of Surgical Complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205–13.PubMedPubMedCentralCrossRef
51.
Bril SI, Chargi N, Wendrich AW, Wegner I, Bol GH, Smid EJ et al. Validation of skeletal muscle mass assessment at the level of the third cervical vertebra in patients with Head and Neck cancer. Oral Oncol. 2021;123.
52.
Chargi N, Ansari E, Huiskamp LFJ, Bol G, de Bree R. Agreement between skeletal muscle mass measurements using computed tomography imaging and magnetic resonance imaging in Head and Neck cancer patients. Vol. 99, Oral Oncol 2019. 2019.
53.
Zwart AT, van der Hoorn A, van Ooijen PMA, Steenbakkers RJHM, de Bock GH, Halmos GB. CT-measured skeletal muscle mass used to assess frailty in patients with Head and Neck cancer. J Cachexia Sarcopenia Muscle. 2019;10(5):1060–9.PubMedPubMedCentralCrossRef
54.
Ufuk F, Herek D, Yüksel D. Diagnosis of Sarcopenia in head and neck computed tomography: cervical muscle mass as a strong indicator of Sarcopenia. Clin Exp Otorhinolaryngol. 2019;12(3):317–24.PubMedPubMedCentralCrossRef
55.
Van den Broeck J, Sealy MJ, Brussaard C, Kooijman J, Jager-Wittenaar H, Scafoglieri A. The correlation of muscle quantity and quality between all vertebra levels and level L3, measured with CT: an exploratory study. Front Nutr. 2023;10.
56.
Zwart AT, Becker JN, Lamers MJ, Dierckx RAJO, de Bock GH, Halmos GB et al. Skeletal muscle mass and sarcopenia can be determined with 1.5-T and 3-T neck MRI scans, in the event that no neck CT scan is performed. Eur Radiol. 2020.
57.
van Vugt JLA, van den Coebergh RRJ, Schippers HJW, Veen KM, Levolger S, de Bruin RWF, et al. Contrast-enhancement influences skeletal muscle density, but not skeletal muscle mass, measurements on computed tomography. Clin Nutr. 2018;37(5):1707–14.PubMedCrossRef
58.
Refos JWJ, Witte BI, de Goede CJT, de Bree R. Shoulder morbidity after pectoralis major flap reconstruction. Head Neck. 2016;38(8):1221–8.PubMedCrossRef
59.
Moukarbel RV, Fung K, Franklin JH, Leung A, Rastogi R, Anderson CM, et al. Neck and shoulder disability following reconstruction with the pectoralis major pedicled flap. Laryngoscope. 2010;120(6):1129–34.PubMedCrossRef
60.
Merve A, Mitra I, Swindell R, Homer JJ. Shoulder morbidity after pectoralis major flap reconstruction for Head and Neck cancer. Head Neck. 2009;31(11):1470–6.PubMedCrossRef
61.
Nguyen S, Thuot F. Functional outcomes of fasciocutaneous free flap and pectoralis major flap for salvage total laryngectomy. Head Neck. 2017;39(9):1797–805.PubMedCrossRef
62.
Jacobi I, Timmermans AJ, Hilgers FJM, van den Brekel MWM. Voice quality and surgical detail in post-laryngectomy tracheoesophageal speakers. Eur Arch Otorhinolaryngol. 2016;273(9):2669–79.PubMedCrossRef
Metadata
Title
Prophylactic pectoralis major flap to compensate for increased risk of pharyngocutaneous fistula in laryngectomy patients with low skeletal muscle mass (PECTORALIS): study protocol for a randomized controlled trial
Authors
Maartje A. van Beers
Caroline M. Speksnijder
Carla H. van Gils
Geert W.J. Frederix
Jan Willem Dankbaar
Remco de Bree
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2024
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-023-11773-7

Other articles of this Issue 1/2024

BMC Cancer 1/2024 Go to the issue

Research

Development of preoperative and postoperative models to predict recurrence in postoperative glioma patients: a longitudinal cohort study

Research

Unraveling cervical cancer screening dilemmas: histopathological insights from VIA and LEEP at bugando medical centre, Mwanza

Research

Identification of FOXP1 as a favorable prognostic biomarker and tumor suppressor in intrahepatic cholangiocarcinoma

Research

A qualitative evaluation of factors influencing Tumor Treating fields (TTFields) therapy decision making among brain tumor patients and physicians

Research

Assessing the genomic feature of Chinese patients with ampullary adenocarcinoma: potential therapeutic targets

Research

A real-world study of the effectiveness and safety of apatinib-based regimens in metastatic triple-negative breast cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits